The Food and Drug Administration (FDA) is advising consumers not to purchase or use Japan Hokkaido Slimming Weight Loss Pills and MEZO Capsules, a product promoted and sold for weight loss on various websites and in some retail stores.
FDA
laboratory analysis confirmed that Japan Hokkaido Slimming Weight Loss
Pills contain sibutramine, benzocaine, phenolphthalein and diclofenac.
Sibutramine
is a controlled substance that was removed from the market in October
2010 for safety reasons. Benzocaine
is a local anesthetic. It is the active ingredient in many
over-the-counter (OTC) products used to relieve pain in the mouth and
gums from a variety of conditions.Phenolphthalein is a chemical that is not an
active ingredient in any approved drug in the United States. Diclofenac
is a non-steroidal anti-inflammatory (NSAID) drug that can cause
increased risk of cardiovascular events, such as heart attack and
stroke.
For Detailed Information on Public Notification on Japan Hokkaido Slimming Weight Loss Capsules CLICK HERE
FDA laboratory analysis confirmed that Mezo Capsules contains benzylsibutramine, a substance structurally similar to sibutramine. Sibutramine is a controlled substance that was removed from the market in October 2010 for safety reasons.
For Detailed Information on Public Notification on MEZO Capsules CLICK HERE
FDA laboratory analysis confirmed that LX1 contains undeclared DMAA, also known as 1,3-dimethylamylamine, methylhexanamine or geranium extract. Ingestion of DMAA can elevate blood pressure and could lead to cardiovascular problems, including heart attack, shortness of breath and tightening of the chest.
For Detailed Information on Public Notification on LX1 CLICK HERE
FDA laboratory analysis confirmed that Best Line Suplemento Alimenticio Capsules contains sibutramine. Sibutramine is a controlled substance that was removed from the market in October 2010 for safety reasons.
For Detailed Information on Public Notification on Best Line Suplemento Alimenticio Capsules CLICK HERE
Consumers should stop using this product immediately and throw it away. Consumers who have experienced any negative side effects should consult a health care professional as soon as possible.
For Detailed Information on Public Notification on Japan Hokkaido Slimming Weight Loss Capsules CLICK HERE
FDA laboratory analysis confirmed that Mezo Capsules contains benzylsibutramine, a substance structurally similar to sibutramine. Sibutramine is a controlled substance that was removed from the market in October 2010 for safety reasons.
For Detailed Information on Public Notification on MEZO Capsules CLICK HERE
FDA laboratory analysis confirmed that LX1 contains undeclared DMAA, also known as 1,3-dimethylamylamine, methylhexanamine or geranium extract. Ingestion of DMAA can elevate blood pressure and could lead to cardiovascular problems, including heart attack, shortness of breath and tightening of the chest.
For Detailed Information on Public Notification on LX1 CLICK HERE
FDA laboratory analysis confirmed that Best Line Suplemento Alimenticio Capsules contains sibutramine. Sibutramine is a controlled substance that was removed from the market in October 2010 for safety reasons.
For Detailed Information on Public Notification on Best Line Suplemento Alimenticio Capsules CLICK HERE
Consumers should stop using this product immediately and throw it away. Consumers who have experienced any negative side effects should consult a health care professional as soon as possible.
No comments:
Post a Comment